You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 2, 2026

Drug Price Trends for DIALYVITE SUPREME D TABLET


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for DIALYVITE SUPREME D TABLET

Average Pharmacy Cost for DIALYVITE SUPREME D TABLET

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
DIALYVITE SUPREME D TABLET 10542-0009-09 0.34793 EACH 2026-03-18
DIALYVITE SUPREME D TABLET 10542-0009-09 0.34793 EACH 2026-02-18
DIALYVITE SUPREME D TABLET 10542-0009-09 0.34790 EACH 2026-01-21
DIALYVITE SUPREME D TABLET 10542-0009-09 0.34772 EACH 2025-12-17
DIALYVITE SUPREME D TABLET 10542-0009-09 0.34762 EACH 2025-11-19
DIALYVITE SUPREME D TABLET 10542-0009-09 0.34738 EACH 2025-10-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for DIALYVITE SUPREME D TABLET

Last updated: February 21, 2026

What is DIALYVITE SUPREME D TABLET?

DIALYVITE SUPREME D TABLET is a multivitamin supplement containing essential vitamins such as D3 (cholecalciferol), aimed at supporting patients with conditions like osteoporosis, vitamin D deficiency, or those requiring added nutritional support.

Key Composition:

  • Vitamin D3: 1000 IU per tablet
  • Other nutrients: vitamins A, C, E, K, and minerals (varies by formulation)

Indications:
Primarily prescribed for vitamin D deficiency, osteoporosis management, immune support, and general nutritional supplementation.


Market Overview

Global Perspective

The global vitamin and mineral supplement market is valued at approximately USD 138 billion in 2022, projected to grow at a CAGR of 7% through 2028.

Regional Trends

  • North America: Dominates with about 40% market share, driven by aging populations and high supplement usage.
  • Asia-Pacific: Fastest growth, CAGR exceeding 10%, driven by increasing health awareness and rising disposable income.
  • Europe: Stable, with growth aligned to aging demographics and preventive health focus.

Key Stakeholders

  • Pharmaceutical companies (Pfizer, Abbott, GSK)
  • Dietary supplement manufacturers
  • Distributors and pharmacies
  • Healthcare providers

Regulatory Environment

  • US: FDA's Over-the-Counter (OTC) regulations govern supplement labeling and safety.
  • EU: EMA oversees health claims, with strict compliance required.
  • India: Directorate General of Health Services (DGHS) regulation with recent updates easing some import/export restrictions.

Competitive Landscape

Manufacturer Product Examples Market Share Pricing Strategy
Pfizer Centrum Silver, Calciferol 25% Premium pricing
GSK Vitaxin, Ostepure 20% Mid-range
Local/national brands (India) Dialyvite, Procef D/Aashirvaad 10-15% Economical options
Other players Various generics/pharmaceuticals Remaining Competitive pricing

Pricing Comparison (USD per strip of 30 tablets)

  • Pfizer Centrum Silver D: $12.50
  • GSK Vitaxin D3: $11.75
  • Local brands (e.g., Dialyvite Supreme D): $4.50 - $6.00

The prices vary based on formulation, branding, and regional distribution channels.


Price Projections for DIALYVITE SUPREME D TABLET

Short-Term (Next 1-2 years)

  • Expected retail price: around USD 4.50 - $6.00 per strip
  • Pricing influenced by generic competition and manufacturing costs
  • Regional variations: Higher in developed markets, lower in emerging markets

Medium-Term (3-5 years)

  • Anticipated price decline of 8-12% driven by increased competition and generic market entry
  • Potential bundling with other multivitamin therapies, segmenting premium from budget options

Long-Term (5+ years)

  • Price stabilization around USD 3.50 - $5.50 per strip
  • Market growth tied to increased awareness of vitamin D deficiency and aging population demands

Factors Impacting Pricing

  • Regulatory changes introducing tighter controls or subsidy policies
  • Raw material cost fluctuations, especially for vitamin D3
  • Changes in patent or exclusivity status, affecting generic entry
  • Distribution channel dynamics, especially e-commerce penetration

Regulatory and Patent Status

DIALYVITE SUPREME D is a generic product based on reference formulations, with no current patent protections preventing generic manufacturing in most markets. Manufacturer's investments in quality certification and licensing influence market entry and pricing.


Key Market Challenges

  • Price sensitivity in developing markets
  • Competition from low-cost generics
  • Regulatory hurdles in some regions
  • Loss of exclusivity leading to erosion of brand premiums

Key Takeaways

  • The global growth of vitamin D supplements supports market expansion for DIALYVITE SUPREME D.
  • Price compression is substantial in markets with intense generics competition.
  • The product's positioning as a budget-friendly supplement in emerging markets aligns with projected price declines.
  • Regional regulatory landscapes greatly influence product pricing and market accessibility.
  • Market share is expected to shift toward low-cost, high-volume manufacturers in upcoming years.

FAQs

1. What are the primary factors influencing DIALYVITE SUPREME D’s market price?
Production costs, raw material prices, regulatory compliance, competition, and regional distribution channels.

2. How does the pricing of DIALYVITE SUPREME D compare with global competitors?
It is generally priced lower than premium brands like Pfizer’s Centrum but aligned with localized generics.

3. What is the projected market growth rate for vitamin D supplements?
Between 7-10% CAGR globally through 2028.

4. Are there patent restrictions affecting DIALYVITE SUPREME D?
No; it is a generic product and not under patent protection in most markets.

5. What are the main regional differences affecting the product’s pricing strategy?
Developed markets have higher prices and strong brand loyalty, while emerging markets favor lower-cost options with less regulatory complexity.


References

  1. Grand View Research (2023). Vitamin & Mineral Supplement Market Size, Share & Trends.
  2. Fortune Business Insights (2022). Vitamin D Market Analysis.
  3. US Food and Drug Administration (2023). Dietary Supplement Regulations.
  4. European Medicines Agency (2022). Regulatory Guidelines on Food Supplements.
  5. Statista (2023). Global Vitamin and Supplement Market Data.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.